Laboratory Corp of America Holdings (LH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory testing, ambulatory monitoring services, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, DNA identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine and hospital services. It also offers drug development services through Covance. It offers its services to managed care organizations, physicians, hospitals, government agencies and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. The company has operations across the US, Columbia, Belgium, Puerto Rico, Japan, China, Singapore, the UK and three Canadian provinces. LabCorp is headquartered in Burlington, North Carolina, the US.

Laboratory Corp of America Holdings (LH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
LabCorp Acquires High-Complexity Genomic Lab From Covance 16
Gamma-Dynacare Medical Acquires Quebec Operations Of Lifelabs 17
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 18
Venture Financing 19
Orig3n Raises USD20 Million in Venture Financing 19
Sera Prognostics Raises USD40 Million in Series C Financing 21
Orig3N Raises USD12.5 Million in Series A Financing 22
Orig3N Raises Funds through Venture Financing 24
Flatiron Health Raises US$130 Million In Series B Financing 25
Private Equity 26
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 26
Partnerships 27
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 27
Laboratory Corp Enters into Partnership with Capital Health 28
Emulate Enters into Agreement with Covance 29
Sequenom Enters into Agreement with University of Colorado Denver 30
Motif Bio Enters into Agreement with Covance 31
Sequenom Enters into Agreement with University Medical Center Hamburg 32
Sequenom Enters into Agreement with Seoul National University Hospital 33
Sequenom enters into an Agreement with University of California 34
Covance Enters into Co-Development Agreement with Sihuan Pharma 35
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 36
Covance Enters into Research Agreement with Frenova Renal Research 37
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 38
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 39
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 40
GNS Healthcare Enters Into Co-Development Agreement With Covance 41
Bayer HealthCare Enters Into Agreement With Covance 42
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 43
Licensing Agreements 45
LabCorp Enters into Licensing Agreement with Transgenomic 45
Equity Offering 46
Sequenom Completes Public Offering Of Common Stock For US$62 Million 46
Debt Offering 48
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 48
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 50
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 52
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 54
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 56
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 57
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 58
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 59
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 60
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 62
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 64
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 65
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 67
Asset Transactions 69
LabCorp Acquires High-Complexity Genomic Lab From Covance 69
Marken Acquires European Kit Building Operation Facility From LabCorp 70
Acquisition 71
LabCorp Acquires Sciformix 71
Eurofins Receives Approval to Acquire Covance from LabCorp 72
LabCorp Acquires Chiltern International for USD1.2 Billion 74
Chiltern International Acquires Integrated Development Associates 76
LabCorp May Acquire Pharmaceutical Product Development 77
LabCorp Acquires Covance for USD6.1 Billion 78
BioLegend Acquires Covance Antibody Services from Covance 80
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 81
Covance Acquires Medaxial 82
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 83
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 84
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 85
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 86
Laboratory Corp of America Holdings - Key Competitors 88
Laboratory Corp of America Holdings - Key Employees 89
Laboratory Corp of America Holdings - Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Recent Developments 95
Strategy And Business Planning 95
Mar 09, 2018: Covance Forms Immunology & Immunotoxicology Unit Focused on Biologic Drug Development 95
Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 96
Financial Announcements 97
Apr 25, 2018: LabCorp Announces Strong 2018 First Quarter Results and Updates 2018 Guidance 97
Feb 06, 2018: LabCorp Reports Net Revenue Of $2.70 Billion In The Fourth Quarter 2017 100
Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance 103
Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 105
Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance 108
Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance 110
Corporate Communications 113
Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 113
Jul 18, 2017: LabCorps William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 114
Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Companys Two Primary Business Segments 115
Legal and Regulatory 116
Dec 11, 2017: LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule 116
Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 117
Product News 118
Nov 16, 2017: Cority Enhances Clinical Testing Solution with LabCorp Interface 118
Other Significant Developments 119
Apr 24, 2018: LabCorp and Mount Sinai Health System Enhance Laboratory Operations to Improve Patient Care 119
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120

List Of Tables

List of Tables
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
LabCorp Acquires High-Complexity Genomic Lab From Covance 16
Gamma-Dynacare Medical Acquires Quebec Operations Of Lifelabs 17
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 18
Orig3n Raises USD20 Million in Venture Financing 19
Sera Prognostics Raises USD40 Million in Series C Financing 21
Orig3N Raises USD12.5 Million in Series A Financing 22
Orig3N Raises Funds through Venture Financing 24
Flatiron Health Raises US$130 Million In Series B Financing 25
Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million 26
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 27
Laboratory Corp Enters into Partnership with Capital Health 28
Emulate Enters into Agreement with Covance 29
Sequenom Enters into Agreement with University of Colorado Denver 30
Motif Bio Enters into Agreement with Covance 31
Sequenom Enters into Agreement with University Medical Center Hamburg 32
Sequenom Enters into Agreement with Seoul National University Hospital 33
Sequenom enters into an Agreement with University of California 34
Covance Enters into Co-Development Agreement with Sihuan Pharma 35
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 36
Covance Enters into Research Agreement with Frenova Renal Research 37
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 38
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 39
Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 40
GNS Healthcare Enters Into Co-Development Agreement With Covance 41
Bayer HealthCare Enters Into Agreement With Covance 42
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 43
LabCorp Enters into Licensing Agreement with Transgenomic 45
Sequenom Completes Public Offering Of Common Stock For US$62 Million 46
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 48
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 50
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 52
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 54
Covance Completes Private Placement Of Notes Due 2025 For US$95 Million 56
Covance Completes Private Placement Of Notes Due 2023 For US$90 Million 57
Covance Completes Private Placement Of Notes Due 2018 For US$15 Million 58
Covance Completes Private Placement Of Notes Due 2020 For US$50 Million 59
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 60
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 62
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 64
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 65
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 67
LabCorp Acquires High-Complexity Genomic Lab From Covance 69
Marken Acquires European Kit Building Operation Facility From LabCorp 70
LabCorp Acquires Sciformix 71
Eurofins Receives Approval to Acquire Covance from LabCorp 72
LabCorp Acquires Chiltern International for USD1.2 Billion 74
Chiltern International Acquires Integrated Development Associates 76
LabCorp May Acquire Pharmaceutical Product Development 77
LabCorp Acquires Covance for USD6.1 Billion 78
BioLegend Acquires Covance Antibody Services from Covance 80
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 81
Covance Acquires Medaxial 82
Gamma-Dynacare Medical Labs Acquires Lab Bio-Medic From Persistence Capital Partners 83
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 84
Gamma-Dynacare Medical Laboratories Acquires MedAxio Insurance Medical Services 85
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 86
Laboratory Corp of America Holdings, Key Competitors 88
Laboratory Corp of America Holdings, Key Employees 89
Laboratory Corp of America Holdings, Other Locations 90
Laboratory Corp of America Holdings, Subsidiaries 91

List Of Figures

List of Figures
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Devices Deals, 2012 to YTD 2018 12

The Jackson Laboratory - Pharmaceuticals and Healthcare - Deals and Alliances Profile

The Jackson Laboratory (JAX) is a biomedical research center that offers clinical genomic solutions. The center provides breeding and rederivation services. It offers cryopreservation and recovery services such as sperm

USD 250 View Report

Laboratory Corporation of America Holdings - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

USD 350 View Report

2018 Consumer Goods Competitive Intelligence: Packaging Corp of America Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes current assessments of more than 1,000 companies worldwide. The assessments include all or some of the following: Organization and

USD 950 View Report

Packaging Corp of America: Performance, Capabilities, Goals and Strategies in the Global Consumer Goods Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available